These is never any mention of Bavi in the articles you keep posting. Why do you refuse to answer the question of when Bavi's patent expires? Please provide a direct answer along with a link for verification.
Why do you think Omeros comes forward now to admit PS Targeting is REQUIRED?
Omeros is targeting the RECEPTOR that associates with PS not PS itself. As I explained many, many times, receptors are good targets because of their much smaller numbers whereas PS is not because so much is exposed on cancer cells as well as on apoptotic cells, the later more being far more common in older patients who are more prone to developing cancer.
News 
Market Data 
Discover 
